- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Kisqali
Synonyms :
ribociclib
Class :
Antineoplastic agents and CDK Inhibitors; Aromatase Inhibitors
ribociclib is indicated in women with (HR)-positive hormone receptor (HER2) human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer
A dose of 600 mg is administered each day orally for the initial 21 days of every 28-day cycle
The medication is continued until the disease is reduced to acceptable toxicity
Dose Adjustments
In case of adverse reactions, the dose is modified or reduced
The pattern of dose reduction goes like this
First dose reduction: 400 mg daily
Second dose reduction: 200 mg daily
In case the patient is unable to tolerate 200 mg daily, discontinue the treatment
Hepatic impairment
In the case of mild Child-Pugh A, there is no dose adjustment required
In case of moderate-to-severe Child-Pugh B or C: Reduce the starting dose to 400 mg/day
Renal impairment
In the case of mild-to-moderate (CrCl ≥30 mL/min): No dose adjustment is necessary
In case of severe (CrCl 15-30 mL/min): reduce the starting dose to 200 mg/day
may enhance the serum concentration of CYP3A4 inhibitors
it enhances the immunosuppressant activity of immunosuppressants
CYP3A4 inhibitors increase the concentration of aprepitant in serum
it enhances the immunosuppressant activity of baricitinib
CYP3A4 inhibitors increase the concentration of bosutinib in serum
it enhances the myelosuppressive activity of cladribine
they decrease the concentration of ribociclib in serum
CYP3A4 inhibitors increase the concentration of eletriptan in serum
it increases the concentration of CYP3A4 substrates in serum
it increases the concentration of ivabradine in serum
it increases the concentration of lonafarnib in serum
it increases the concentration of nisoldipine in serum
it increases the concentration of ribociclib in serum
CYP3A4 inhibitors increase the concentration of simeprevir in serum
immunosuppressants decrease the activity of tertomotide
immunosuppressants increase the immunosuppressive activity of upadacitinib
vaccines: immunosuppressants decrease the efficacy of vaccines
ribociclib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
ribociclib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
ribociclib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
ribociclib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
ribociclib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
both lapatinib and ribociclib increase the QTc interval
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ribociclib
CYP3A4 inhibitors increase the concentration of abemaciclib in serum
CYP3A4 inhibitors increase the concentration of amlodipine in serum
CYP3A4 inhibitors increase the concentration of bortezomib in serum
CYP3A4 inhibitors increase the concentration of cabozantinib in serum
CYP3A4 inhibitors increase the concentration of copanlisib in serum
CYP3A4 inhibitors increase the concentration of dabrafenib in serum
CYP3A4 inhibitors increase the concentration of ebastine in serum
CYP3A4 inhibitors increase the concentration of fosamprenavir in serum
CYP3A4 inhibitors decrease the concentration of active metabolites of ifosfamide in serum
CYP3A4 inhibitors increase the concentration of larotrectinib in serum
CYP3A4 inhibitors increase the concentration of manidipine in serum
CYP3A4 inhibitors increase the concentration of naldemedine in serum
CYP3A4 inhibitors increase the concentration of oliceridine in serum
CYP3A4 inhibitors increase the concentration of pimavanserin in serum
CYP3A4 inhibitors increase the concentration of ranolazine in serum
CYP3A4 inhibitors increase the concentration of sildenafil in serum
CYP3A4 inhibitors increase the concentration of tamsulosin in serum
CYP3A4 inhibitors increase the concentration of zopiclone in serum
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
ribociclib: they may diminish the serum concentration of CYP3A4 Inducers
ribociclib: they may diminish the serum concentration of CYP3A4 Inducers
ribociclib: they may diminish the serum concentration of CYP3A4 Inducers
ribociclib: they may diminish the serum concentration of CYP3A4 Inducers
ribociclib: they may diminish the serum concentration of CYP3A4 Inducers
It may enhance the effects when combined with tasimelteon by affecting CYP3A4 metabolism
when both drugs are combined, there may be an increased effect of cabozantinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
has a synergistic effect over brentuximab vedotin by showing altered intestinal/hepatic CYP3A4 enzyme metabolism.
when both drugs are combined, there may be a reduced metabolism of erlotinib
may increase the serum concentration and toxic effects of tamoxifen
the effect of ribociclib is increased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolismlorl
it decreases the concentration of tamoxifen in serum
Inhibits the CYP3A4 metabolism of busulfan and increases the effect.
ribociclib increases the effect of ixazomib by altering intestinal/hepatic CYP3A4 enzyme metabolism
it increases the effect or level of osimertinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
it increases by affecting the hepatic enzyme CYP3A4 metabolism
Frequency defined:
>10%
Leukocyte count decreased
Neutrophil count decreased
Neutropenia
Hemoglobin decreased
Nausea
Lymphocyte count decreased
Neutropenia
Neutrophil count decreased
AST/ALT increased
Fatigue
Diarrhea
Leukopenia
Alopecia
Leukocyte count decreased
Platelets decreased
Vomiting
Constipation
Headache
Leukopenia
Back pain
Creatinine increased
Decreased appetite
Anemia
Abnormal LFTs
Rash
Pruritus
Pyrexia
Phosphorus decreased
Peripheral edema
Stomatitis
Insomnia
Dyspnea
Lymphopenia
Urinary tract infection
Abdominal pain
Potassium decreased
1-10%
Neutropenia
Pregnancy consideration: The drug is toxic and unsafe for pregnant women and the developing fetus.
Breastfeeding warnings: No data on the excretion of ribociclib in breast milk is available. Because of possible serious effects, women are advised to breastfeed three weeks after the last dose of ribociclib.
Pregnancy category:
Patient information leaflet
Generic Name: ribociclib (Rx)
Pronounced: RY-boh-SY-klib
Why do we use ribociclib?
Ribociclib is an anti-cancer agent of the CDK Inhibitor and aromatase inhibitor class. It treats breast cancer.
ADVERTISEMENT
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
